Auctus Capital Partners, a key player in the PharmaLex transaction, saw the successful sale of the PharmaLex Group to AmerisourceBergen Corporation for €1.28 billion. This significant deal, announced in 2022 and expected to close in March 2023, underscores Auctus Capital Partners’ strategic investment approach in the pharmaceutical services sector.
PharmaLex, a leading provider of specialized services to the pharmaceutical industry, offers a comprehensive suite of solutions ranging from drug development and regulatory affairs to pharmacovigilance and market access. With a global presence and a strong technology-driven approach, PharmaLex enables pharmaceutical companies to navigate complex regulatory landscapes and bring their products to market efficiently. The acquisition by AmerisourceBergen, a Fortune 10 company, positions PharmaLex for further growth and expansion within the global healthcare market.
Auctus Capital Partners, alongside PharmaLex Holding GmbH, was advised by the international law firm McDermott Will & Emery throughout this complex transaction. Dr. Stephan Rau, a leading lawyer at McDermott and a long-time advisor to Auctus Capital Partners and PharmaLex, played a crucial role in navigating the legal and regulatory aspects of the deal. His expertise in mergers and acquisitions, private equity, and healthcare regulatory matters, coupled with the support of a global team of lawyers, ensured a successful outcome for Auctus Capital Partners. The team also included other key members such as Dr. Germar Enders and Dr. Nadine Hartung, specializing in corporate law and M&A.
The collaboration between Auctus Capital Partners and McDermott extended beyond this transaction. Dr. Rau has advised Auctus Capital Partners on numerous acquisitions within the pharmaceutical sector since 2015, particularly in the United States, leveraging McDermott’s extensive experience in life sciences and healthcare. Notably, McDermott also advised on the acquisition of Phlexglobal, a UK-based technology platform, by PharmaLex earlier in 2022. This prior engagement solidified the strong working relationship between Auctus Capital Partners and McDermott, paving the way for a smooth and efficient process in the AmerisourceBergen transaction. The successful divestment of PharmaLex represents a significant achievement for Auctus Capital Partners, showcasing their ability to identify and nurture high-growth companies within the pharmaceutical industry.
The sale of PharmaLex to AmerisourceBergen signifies a major development in the pharmaceutical services sector. For Auctus Capital Partners, this successful exit underscores their strategic investment acumen and expertise in fostering growth within their portfolio companies. The transaction also highlights the increasing consolidation within the pharmaceutical industry, driven by the demand for specialized services and innovative solutions.
